Document is current

Article History

Received: 22 April 2024

Revised: 17 May 2024

Accepted: 4 June 2024

First Online: 18 June 2024

Declarations

:

: SF: SF received institutional funding from BioNTech SE in relation to the submitted work, received personal honoraria from Kyowa Kirin and Recordati Rare Diseases (speaker’s honoraria), as well as institutional grants from Neracare and SkylineDX outside the submitted work.OTP: OTP has no conflict of interest to declare.MH: MH has no conflict of interest to declare.VA: VA has no conflict of interest to declare.CMS: CMS has no conflict of interest to declare.CS: CS reports institutional grants from Illumina and research grants from BMS Stiftung Immunonkologie and Westdeutsche Studiengruppe GmbH outside the submitted work.AL: AL has no conflict of interest to declare.MA: MA has no conflict of interest to declare.HW: HW has no conflict of interest to declare.EB: EB has no conflict of interest to declare.MK: MK has no conflict of interest to declare.DS: DS has no conflict of interest to declare.KC: KC is an employee at BioNTech and holds securities from BioNTech SE.IB: IB is an employee at BioNTech and holds securities from BioNTech SE.CF: CF is an employee at BioNTech and holds securities from BioNTech SE.MP: MP is an employee at BioNTech and holds securities from BioNTech SE.ML: ML is an employee at BioNTech and holds securities from BioNTech SE.PB: PB is an employee at BioNTech and holds securities from BioNTech SE.ÖT: ÖT is co-founder, management board member, and employee at BioNTech. ÖT has a leadership role at the Helmholtz Institute HI-TRON Mainz and is a founding member of TRON Translational Oncology Mainz. ÖT holds a professorship at the Johannes Gutenberg University. ÖT is an inventor on patents and patent applications related to RNA technology. ÖT holds securities from BioNTech SE.US: US is co-founder, management board member, and employee at BioNTech. US has a leadership role at the Helmholtz Institute HI-TRON Mainz and is a founding member of TRON Translational Oncology Mainz. He holds a professorship at the Johannes Gutenberg University as professor in 2022 and was awarded with German Future Prize 2021. US is an inventor on patents and patent applications related to RNA technology. US holds securities from BioNTech SE.LF: LF has/had advisory roles for Novartis, Sanofi, Philogen, and Bristol-Myers Squibb. LF received research support by Hookipa Pharma, Mundipharma and the Novartis Foundation. All outside the submitted work.IBB: IBB received institutional funding from BioNTech SE in relation to the submitted work. IBB had advisory roles for Alexion outside the submitted work.